Post by NEMERA

Securing clinical outcomes starts with selecting patient-centric devices In cardiovascular-kidney-metabolic care, pharma companies must integrate many factors into their delivery device selection to create a patient-centric and clinically effective drug delivery experience. In the case of obesity, patients’ comorbidities, education, engagement with treatment, therapy preferences, lifestyle, previous interactions with medical devices, geographical factors, and out-of-pocket cost should all be taken into consideration beyond BMI. Some of the most important factors to securing a positive clinical outcome are limiting the risk of underdose and increasing patient adherence. At Nemera, our pen injector platforms are designed with unique features to support these two important factors. Discover our pen injector platforms: urlr.me/64gEUX